Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect Syros Pharmaceuticals to post earnings of ($0.67) per share for the quarter.
Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.09. On average, analysts expect Syros Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Syros Pharmaceuticals Trading Down 8.0 %
SYRS stock opened at $2.07 on Friday. The company has a market capitalization of $55.33 million, a PE ratio of -0.41 and a beta of 1.59. Syros Pharmaceuticals has a one year low of $1.43 and a one year high of $8.17. The company’s 50 day moving average price is $1.84 and its two-hundred day moving average price is $4.10. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.46 and a current ratio of 3.46.
Insider Activity at Syros Pharmaceuticals
Analyst Upgrades and Downgrades
SYRS has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. StockNews.com raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. JMP Securities decreased their price target on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright lowered their price target on shares of Syros Pharmaceuticals from $15.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th.
View Our Latest Research Report on Syros Pharmaceuticals
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Articles
- Five stocks we like better than Syros Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Are Some of the Best Large-Cap Stocks to Buy?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Investing in Construction Stocks
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.